Understand the source comparison
How to Use ARA-290 for Sarcoidosis Protocol: Treatment Duration Comparison
4 weeks (short-term) 2–4mg daily Minimal symptom change; inflammatory markers largely unchanged; too brief for IRR-mediated cytokine modulation to manifest Insufficient duration for meaningful efficacy evaluation. ARA-290 requires sustained signalling 8 weeks
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 4 weeks (short-term)
- 2–4mg daily
- Minimal symptom change; inflammatory markers largely unchanged; too brief for IRR-mediated cytokine modulation to manifest
- Insufficient duration for meaningful efficacy evaluation. ARA-290 requires sustained signalling
- 8 weeks (standard)
- Moderate symptom improvement (20–30% reduction in pain/fatigue scores); possible reduction in TNF-α but inconsistent CRP response
- Minimum duration to observe clinical benefit; aligns with Groningen trial's primary endpoint window
- 12 weeks (extended)
- Maximal symptom improvement (30–40% reduction); sustained cytokine modulation; diminishing returns beyond this point
- Optimal duration for most sarcoidosis applications; extending further rarely yields proportional gains
- 16+ weeks (maintenance)
- 1–2mg daily or every other day
- Symptom stabilisation; used in some protocols to prevent relapse after initial 12-week course
- Evidence for maintenance dosing is limited; primarily anecdotal rather than trial-supported